FDA Grants Fast Track to Elticertinib for Lung Cancer
The investigational EGFR exon 20 insertion therapy from Laboratoires Pierre Fabre received the designation based on nonclinical and preliminary Phase 1/2 trial data.
Updated on Nov. 17, 2026 in Cancer

The U.S. Food and Drug Administration granted Fast Track designation to elticertinib, an investigational oral tyrosine kinase inhibitor, for adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease has progressed on platinum-based chemotherapy and amivantamab. The designation was announced on November 17, 2026, by Laboratoires Pierre Fabre, based in Castres, France.
Why it matters
Fast Track designation is intended to expedite development and review of therapies for serious conditions with significant unmet medical need, and it provides more frequent interaction with the FDA and eligibility for rolling and priority review if criteria are met. The company said it will engage more closely with the agency to accelerate development.
The designation rests on preliminary efficacy results from the ongoing Phase 1/2 trial NCT06043817 and nonclinical data, while the trial's efficacy figures are not disclosed in the announcement. EGFR mutations account for up to 38% of NSCLC tumors and exon 20 insertions affect up to 10% of EGFR-mutated patients.
The players
Laboratoires Pierre Fabre
Laboratoires Pierre Fabre is a French pharmaceutical company headquartered in Castres, France, that develops oncology and other prescription medicines.
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is the federal agency responsible for regulating drugs, biologics and medical devices sold in the United States, including granting expedited development designations.
The details
Elticertinib, also known as PFL-721 and previously STX-721, is an orally bioavailable, irreversible, highly selective investigational tyrosine kinase inhibitor that targets EGFR and ERBB2 (HER2) exon 20 insertion mutations. The designation covers patients whose disease has progressed despite both platinum-based chemotherapy and amivantamab.
Timeline
November 17, 2026: FDA Fast Track designation for elticertinib announced.
Big Picture
The grant applies the FDA's Fast Track program, created under the Food and Drug Administration Modernization Act of 1997, to a targeted therapy for a biomarker-defined NSCLC subgroup. It follows the pattern of expedited designations used for oncology drugs that address patients who have exhausted existing targeted options.
Patients with EGFR exon 20 insertion NSCLC whose disease has progressed on chemotherapy and amivantamab may eventually have access to an oral option if elticertinib advances through development. The designation does not yet change treatment availability, and patients should discuss current options with their oncology team.
The takeaway
Fast Track designation signals regulatory support for therapies targeting rare mutation subsets, but approval depends on results still to come from the ongoing trial. Patients and caregivers should watch for updated efficacy data before drawing conclusions about clinical benefit.
Further reading
Explore more on Cancer research and treatment developments worldwide.



